Weik Capital Management Buys 3,105 Shares of Zoetis Inc. $ZTS

Key Points

• Weik Capital Management increased its stake in Zoetis Inc. by 82.6% during the first quarter, bringing its total ownership to 6,865 shares valued at approximately $1.13 million.
• Several analysts have recently revised their ratings on Zoetis, with Piper Sandler raising its target price to $215, while others like Stifel Nicolaus and Leerink Partners downgraded their ratings and reduced their price objectives.
• Zoetis announced a quarterly dividend of $0.50 per share, which will be paid on September 3rd, yielding an annualized rate of 1.3% with a payout ratio of 34.42%.

Weik Capital Management raised its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 82.6% in the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 6,865 shares of the company's stock after acquiring an additional 3,105 shares during the period. Weik Capital Management's holdings in Zoetis were worth $1,130,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Navigoe LLC bought a new stake in shares of Zoetis in the 4th quarter valued at $30,000. Cornerstone Planning Group LLC boosted its stake in Zoetis by 79.3% in the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock worth $30,000 after purchasing an additional 88 shares during the period. Migdal Insurance & Financial Holdings Ltd. boosted its stake in Zoetis by 87.6% in the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company's stock worth $42,000 after purchasing an additional 120 shares during the period. Sound Income Strategies LLC boosted its stake in Zoetis by 141.4% in the 1st quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock worth $46,000 after purchasing an additional 164 shares during the period. Finally, Bfsg LLC boosted its stake in Zoetis by 614.6% in the 1st quarter. Bfsg LLC now owns 293 shares of the company's stock worth $48,000 after purchasing an additional 252 shares during the period. Institutional investors own 92.80% of the company's stock.

Insider Buying and Selling

In related news, EVP Roxanne Lagano sold 652 shares of Zoetis stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total transaction of $110,840.00. Following the completion of the transaction, the executive vice president owned 15,129 shares in the company, valued at approximately $2,571,930. This trade represents a 4.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.16% of the company's stock.

Zoetis Stock Down 1.2%

Shares of Zoetis stock traded down $1.83 during trading hours on Monday, reaching $152.28. 2,158,515 shares of the company's stock were exchanged, compared to its average volume of 3,678,922. The company has a 50 day moving average of $154.69 and a two-hundred day moving average of $158.90. Zoetis Inc. has a fifty-two week low of $139.70 and a fifty-two week high of $200.33. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. The stock has a market cap of $67.49 billion, a P/E ratio of 26.21, a P/E/G ratio of 2.47 and a beta of 0.88.

Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The company had revenue of $2.46 billion for the quarter, compared to analysts' expectations of $2.41 billion. During the same period in the prior year, the firm earned $1.56 EPS. Zoetis's quarterly revenue was up 4.2% compared to the same quarter last year. On average, sell-side analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, July 18th will be issued a dividend of $0.50 per share. The ex-dividend date is Friday, July 18th. This represents a $2.00 dividend on an annualized basis and a yield of 1.3%. Zoetis's dividend payout ratio (DPR) is presently 34.42%.

Wall Street Analysts Forecast Growth

ZTS has been the subject of a number of research analyst reports. Leerink Partnrs lowered shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Leerink Partners lowered shares of Zoetis from an "outperform" rating to a "market perform" rating and reduced their target price for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Stifel Nicolaus lowered shares of Zoetis from a "buy" rating to a "hold" rating and reduced their target price for the stock from $165.00 to $160.00 in a research note on Wednesday, June 18th. Piper Sandler upped their target price on shares of Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research note on Monday, August 11th. Finally, UBS Group reduced their price objective on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research note on Wednesday, May 7th. Four research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, Zoetis has a consensus rating of "Moderate Buy" and a consensus target price of $202.43.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.